[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clinical-stage-i-gastroesophageal-junction-adenocarcinoma-ajcc-v8\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clinical-stage-i-gastroesophageal-junction-adenocarcinoma-ajcc-v8":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,81,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100347294","phase-3-comparing-proton-therapy-to-photon-radiation-therapy-for-esophageal-cancer-100347294",false,"NCT03801876","Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer","Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer","Inclusion Criteria:\n\n* PRIOR TO STEP 1 REGISTRATION:\n* Histologically proven diagnosis of adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II)\n* Stage I-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition based on the following diagnostic workup:\n\n  * History\u002Fphysical examination\n  * Whole-body fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)\u002Fcomputed tomography (CT) with or without contrast (preferred) or chest\u002Fabdominal (include pelvic if clinically indicated) CT with contrast\n\n    * For patients who DID NOT receive induction chemotherapy, scan must occur within 30 days prior to Step 1 registration\n    * For patients who DID receive induction chemotherapy, scan must occur:\n\n      * Within 30 days after final induction chemotherapy dose; OR\n      * Within 30 days prior to Step 1 registration\n    * Note: Patients who had prior endoscopic mucosal resection (EMR) with a diagnosis of AJCC stage I-IVA, excluding T4b, esophageal cancer are eligible\n* Surgical consultation to determine whether or not the patient is a candidate for resection after completion of chemoradiation\n* Induction chemotherapy for the current malignancy prior to concurrent chemoradiation allowed if last dose is no more than 90 days and no less than 10 days prior to Step 1 registration; only FOLFOX, CAPOX, durvalumab-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) (D-FLOT) and FLOT will be allowed as the induction chemotherapy regimen\n* Age ≥ 18\n* Zubrod performance status 0, 1, or 2\n* Absolute neutrophil count (ANC) (within 30 days prior to Step 1 registration)\n\n  * For patients who DID NOT receive induction chemotherapy: ANC ≥ 1,500 cells\u002Fmm\\^3\n  * For patients who DID receive induction chemotherapy: ANC ≥ 1,000 cells\u002Fmm\\^3\n* Platelets (within 30 days prior to Step 1 registration)\n\n  * For patients who DID NOT receive induction chemotherapy: Platelets ≥ 100,000\u002FuL\n  * For patients who DID receive induction chemotherapy: Platelets ≥ 75,000\u002FuL\n* Hemoglobin ≥ 8.0 g\u002Fdl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable) (within 30 days prior to Step 1 registration)\n* Serum creatinine ≤ 1.5 X upper limit of normal (ULN) or creatinine clearance \\> 40 mL\u002Fmin estimated by Cockcroft-Gault formula (within 30 days prior to Step 1 registration)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 30 days prior to Step 1 registration)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN (within 30 days prior to Step 1 registration)\n* Negative pregnancy test (serum or urine) within 14 days prior to Step 1 registration for women of child bearing potential\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry\n\nExclusion Criteria:\n\n* Cervical esophageal cancers arisen from 15-18 cm from the incisors\n* Patients with T4b disease according to the AJCC 8th edition\n* Definitive clinical or radiologic evidence of metastatic disease\n* Any active malignancy within 2 years of study registration that may alter the course of esophageal cancer treatment\n* Prior thoracic radiotherapy that would result in overlap of radiation therapy fields\n* Severe, active co-morbidity defined as follows:\n\n  * Active uncontrolled infection requiring IV antibiotics at the time of Step 1 registration\n  * Uncontrolled symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia not controlled by any device or medication at the time of Step 1 registration\n  * Myocardial infarction within 3 months prior to Step 1 registration\n* Pregnant and\u002For nursing females\n* Human immunodeficiency virus (HIV) positive with CD4 count \\\u003C 200 cells\u002Fmicroliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells\u002Fmicroliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive\n* PRIOR TO STEP 2 REGISTRATION:\n* Unable to obtain confirmation of payment coverage (insurance or other) for either possible radiation treatment","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Clinical Stage I Esophageal Adenocarcinoma AJCC v8","Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Thoracic Esophagus Squamous Cell Carcinoma","RECRUITING","2026-06-22",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":43},"2019-06-26",{"date":47,"type":20},"2031-12-21",{"name":49,"class":50},"NRG Oncology","OTHER",96,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100626734","individually-tailored-supervised-remote-exercise-intervention-to-improve-physical-function-for-stage-i-iii-gastroesophageal-cancer-survivors-precise-trial-100626734","NCT07439484","Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial","A Pilot Study of an Individually Tailored, Supervised, Remotely Delivered Exercise Intervention to Improve Physical Function in Survivors of Gastroesophageal Cancer (PRECISE Study)","PRECISE","Inclusion Criteria:\n\n* Adults ≥ 18 years old at the start of study treatment\n* Diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric cancer. Histology can be adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma\n* Treated with at least one systemic therapy (chemotherapy or immunotherapy) and within 12 months of completing curative intent gastroesophageal cancer (GEC) treatment\n* Have evidence of physical function impairment, defined as a SPPB score of \\\u003C 12) at baseline\n* Ability to understand English and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients with stage I disease who underwent endoscopic resection or surgery alone without perioperative systemic therapy\n* Patients with stage IV disease or unresectable locally advanced disease taking a palliative treatment approach without a clearly defined end of treatment\n* Patients currently receiving ongoing systemic therapy for GEC or another malignancy\n* Patients who are unable to provide informed consent\n* Any other condition or pre-existing co-morbidity that would, in the Investigator's judgment, contraindicate the participation in the study due to safety concerns with study procedures\n* Currently participating in another exercise intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion\u002Ffatigue, or cognitive function",{"count":61,"type":20},20,[63],"NA","This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal cancer survivors. Modern treatments for gastroesophageal cancer are effective at treating the cancer but are often aggressive, can be difficult for patients to tolerate, and can lead to significant debilitation and a loss of independence. Exercise is one promising intervention that could improve physical function in patients with gastroesophageal cancer after finishing systemic treatment. Home based exercise interventions in patients with cancer during and after chemotherapy can improve fatigue and function. An individually tailored, supervised, remote exercise intervention may improve physical function for stage I-III gastroesophageal cancer survivors.",[66,27,67,28,29,30,68,31,32,33,69,34],"Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8","Clinical Stage I Gastric Cancer AJCC v8","Clinical Stage II Gastric Cancer AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","NOT_YET_RECRUITING","2026-05-07",{"date":73,"type":43},"2026-05-11",{"date":75,"type":20},"2026-09-01",{"date":77,"type":20},"2028-09-01",{"name":79,"class":50},"Jonsson Comprehensive Cancer Center",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100522137","phase-2-preoperative-hypofractionated-radiotherapy-with-folfox-for-esophageal-or-gastroesophageal-junction-adenocarcinoma-100522137","NCT06078709","Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal\u002FGastroesophageal Junction Adenocarcinoma (PHOX)","PHOX","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological confirmation of esophageal or gastroesophageal junction adenocarcinoma, American Joint Committee on Cancer (AJCC) 8th edition stage T1-4N0-3M0\n* Candidate for trimodality therapy: neoadjuvant chemo (immuno) therapy, chemoradiation, and esophagectomy\n* Surgical consultation has confirmed that patient is an appropriate candidate for esophagectomy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Negative pregnancy test done ≤ 7 days prior to chemotherapy, for women of childbearing potential only\n* Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Willing to provide blood and tissue samples for correlative research purposes\n\nExclusion Criteria:\n\n* Clinical or biopsy-proven distant metastatic disease (AJCC 8th edition stage TanyNanyM1)\n* Cervical or upper esophageal tumor\n* Prior chemotherapy or radiotherapy for esophageal cancer or history of radiotherapy to the thorax\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with proper assessment of adverse events\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm or other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception",{"count":90,"type":20},99,[92],"PHASE2","This phase II trial tests how well preoperative (prior to surgery) radiation therapy with fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX) works for the treatment of stage I-III esophageal or gastroesophageal junction adenocarcinoma. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Fluorouracil stops cells from making deoxyribonucleic acid (DNA) and it may kill tumor cells. Leucovorin is not a chemotherapy medication but is given in conjunction with chemotherapy. Leucovorin is used with the chemotherapy medication fluorouracil to enhance the effects of the fluorouracil, in other words, to make the drug work better. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Giving preoperative hypofractionated radiation with fluorouracil and oxaliplatin may kill more tumor cells in patients with stage I-III esophageal or gastroesophageal junction adenocarcinoma.",[26,28,29,31,32,34],"2026-04-17",{"date":97,"type":43},"2026-04-20",{"date":99,"type":43},"2023-11-20",{"date":101,"type":20},"2027-05-30",{"name":103,"class":50},"Mayo Clinic",3,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":80},"100632709","a-prospective-study-of-physical-function-in-adults-who-receive-systemic-therapy-for-stage-i-iii-gastroesophageal-cancer-fast-go-study-100632709","NCT07517211","A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study","A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer (FAST-GO)","Inclusion Criteria:\n\n* \\* Adults ≥ 18 years old at the start of study treatment.\n\n  * New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma.\n  * Plan to start systemic therapy for resectable or potentially resectable disease.\n  * Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* \\* Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy.\n\n  * Metastatic disease at the time of diagnosis.\n  * Patients who are unable to provide informed consent.\n  * Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n  * Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.",{"count":113,"type":20},72,"OBSERVATIONAL","This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.",[26,27,67,28,29,30,68,31,32,33,69,34],"2026-04-03",{"date":119,"type":43},"2026-04-08",{"date":121,"type":20},"2026-05-01",{"date":123,"type":20},"2029-05-01",{"name":79,"class":50}]